Gohel M.C., Par R.K., Patel K.D.
L.M. College Of Pharmacy, IN
Keywords: glibenclamide, nanoparticles, nasal, stearic acid
To provide an alternative route (non-swallowing) and compliance to patient (controlled release), nasal delivery of sulfonylureas is one of the best option among other routes for type II diabetes. Glibenclamide was selected as a model drug for our present investigation since its oral absorption is affected by presence of food and drug has been found to be first passed 50-60% by hepatic enzymes. Glibenclamide loaded solid lipid Nanoparticles dispersion was prepared for controlled nasal drug delivery using Stearic acid as a lipid in the concentration of 3.6% by 22 full factorial central composite design. Poloxamer 188 (1.78%) was used as solublizers and stabilizer. Menthol IP (0.05%) was used as nasal decongestant and permeation enhancer. Finally the in-situ gel was formed using Carbopol 934P. The prepared formulation showed good diffusion of about 90.59% in 24 hours of application, particle size analysis was done using SEM and shown size of 290 to 420nm and the pH of formulation were found to be 6.2 to 6.4. The formulated dosage form of Glibenclamide was stable, since the stability study was carried out for two months at 40°C ± 2°C and 75% RH ± 5% RH. Glibenclamide loaded solid lipid Nanoparticles dispersion is an ideal dosage form for controlled mode of nasal drug delivery, and can be exploited for other such low dose drug molecules also.
Journal: TechConnect Briefs
Volume: 2, Nanotechnology 2009: Life Sciences, Medicine, Diagnostics, Bio Materials and Composites
Published: May 3, 2009
Pages: 68 - 71
Industry sector: Medical & Biotech
Topics: Biomaterials, Materials for Drug & Gene Delivery
ISBN: 978-1-4398-1783-4